Mitigating Cardiovascular Risk in Type 2 Diabetes with Oral Semaglutide – CME by Novo Nordisk

Date: 21 March, 2025

Dr. Sudhir Bhandari contributed to the academic programme at CME by Novo Nordisk with a session focused on Mitigating Cardiovascular Risk in Type 2 Diabetes with Oral Semaglutide.

Programme: CME by Novo Nordisk
Academic Focus: Mitigating Cardiovascular Risk in Type 2 Diabetes with Oral Semaglutide

Event Gallery